Nedd4

Manufactured by Merck Group

NEDD4 is a lab equipment product manufactured by Merck Group. It is an E3 ubiquitin-protein ligase that plays a role in the ubiquitination and subsequent proteasomal degradation of target proteins. The core function of NEDD4 is to facilitate the labeling of substrate proteins with ubiquitin, which targets them for destruction by the proteasome.

Automatically generated - may contain errors

Lab products found in correlation

E2 ubch5a, by R&D Systems (1 mentions) His ub variants, by R&D Systems (1 mentions) E1 ube1, by R&D Systems (1 mentions) Igf 1r, by Cell Signaling Technology (1 mentions) Pakt s473, by Cell Signaling Technology (1 mentions)

Close spelling variants of this product

Anti-NEDD4 Anti-NEDD4 rabbit polyclonal antibody

2 protocols using nedd4

In Vitro Ubiquitination of PTEN

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vitro ubiquitination, 400 ng of purified Flag-PTEN from 293 cells was incubated with 40 ng E1 (UBE1) (E-305 Boston Biochem), 500 ng E2 (UbcH5a) (E2–616 Boston Biochem), 10 μg His-Ub variants (Boston Biochem), 8 mM ATP, 1× ligase reaction buffer [Fisher Scientific (Thermo Fisher Scientific) # B71], and 1× Energy regeneration system (Boston Biochem #B-10), 400 ng NEDD4 (Sigma Aldrich # SRP0226), and 400 ng WWP1 (Sigma Aldrich # SRP0229) at 37°C for 1 hour in 25 μl of reaction mixture.

Lee Y.R., Chen M., Lee J.D., Zhang J., Lin S.Y., Fu T.M., Chen H., Ishikawa T., Chiang S.Y., Katon J., Zhang Y., Shulga Y.V., Bester A.C., Fung J., Monteleone E., Wan L., Shen C., Hsu C.H., Papa A., Clohessy J.G., Teruya-Feldstein J., Jain S., Wu H., Matesic L., Chen R.H., Wei W, & Pandolfi P.P. (2019). Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science (New York, N.Y.), 364(6441), eaau0159.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Gastric Tumor

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC for the target molecules was performed on single serial sections made from xenograft tumor samples and tissue microarray chips (Department of Pathology, Fourth Military Medical University). The microarray contained 30 human gastric tumor samples and 30 adjacent normal tissue samples. The slides were probed with antibodies of NEDD4 (Sigma-Aldrich; R36446; 1:200), IGF1R (Cell Signaling Technology; 3027 S; 1:100), and p-Akt s473 (Cell Signaling Technology, 4060 S; 1:100). Immunohistochemistry photographs were scanned by Pannoramic (Santa Clara, CA, USA) MIDI and quantified with histochemistry score (H-Score) by Quant center.

Wang K., Yu Y., Wang W., Jiang Y., Li Y., Jiang X., Qiao Y., Chen L., Zhao X., Liu J., Yang A., Li J, & Zhang R. (2023). Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer. Oncogene, 42(14), 1072-1087.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!